Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05767346 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT05767346 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 175 participants.
The verdict
NCT05767346, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
Interventions
- DRUG Placebo to match aficamten
- DRUG Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- DRUG Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg)
- DRUG Placebo to match metoprolol succinate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-06-20 |
| Est. Completion | 2025-03-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05767346
The ClinicalTrials.gov registry entry for NCT05767346 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo to match aficamten is the first listed.
NCT05767346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05767346 about?
NCT05767346 is a clinical study titled "Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM". The purpose of this study is to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction
What is the current status of trial NCT05767346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2023-06-20. Estimated completion is 2025-03-28.
What interventions are being tested in trial NCT05767346?
The interventions under investigation include: Placebo to match aficamten (DRUG), Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg) (DRUG), Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg) (DRUG), Placebo to match metoprolol succinate (DRUG).
Who is sponsoring clinical trial NCT05767346?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.